GlycoVaxyn AG Phase I Clinical Study Shows Positive Data with Shigella Dysenteriae Vaccine Candidate

SCHLIEREN, Switzerland--(BUSINESS WIRE)--GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.

Back to news